FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2 Tyrosine Kinase Domain Activating Mutations By Ogkologos - August 29, 2025 645 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Beamion LUNG-1 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR FDA Approves Updated Drug Labelling Including New Indications and Dosing Regimens... January 9, 2023 FDA Approves Nivolumab for Adjuvant Treatment of Stage IIB/C Melanoma October 26, 2023 Neoadjuvant Chemoimmunotherapy Superior to Neoadjuvant Chemotherapy with Event-Free Survival Benefit in... April 10, 2024 Lorlatinib Slows Growth of ALK-Positive Lung Cancers, May Prevent Brain Metastases July 10, 2024 Load more HOT NEWS One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides... Resilience Isn’t About Bouncing Back Hundreds Of Thousands Of Peruvian Women Were Forcibly Sterilized, And Now... What to Know About Using Activated Charcoal During Cancer
